Here, BioMarin's Nimi Chhina explains the class-specific considerations for cell and gene therapy products that industry and regulators alike can collectively consider to drive policy development.
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: